GLENMARK - Glenmark Pharmaceuticals

Glenmark Pharmaceuticals

GLENMARK · Pharma > Pharmaceuticals & Drugs · Chairman: Glenn Saldanha · MD: Glenn Saldanha · Listing date: Feb. 9, 2000 · Employees: 10964 · Mumbai · http://www.glenmarkpharma.com

Stock Price vs Company Growth

0.6%

2.7%

34.9%

66.9%

52.5%

59.0%

39.7%

10y

7.8%

all

11.7%

🤔 How to analyze this graph?

Last Traded Price

₹ 2,240 0.6%

1,339

2,286

Company Overview

Sales

13,322 Cr

Growth: 11.7%

Profit after Tax

1,047 Cr

Growth: -695.5%

Large Cap

63,207 Cr

P/E: 60.0x

Industry P/E: 33.3x

Fundamentals

Sales (Cr)	₹ 13,322
Growth	11.7%
EBITDA	17.7%
P/S	4.7x
Dividend	0.1%
P/E	60.0x
Book Value	₹ 314
PEG Ratio	5.1x
ROE	12.2%
P/B	7.1x

Shareholding Pattern

Institutions

Qualified Institutional Buyer

4.74 %

Hsbc Pooled Investment Fund - Hsbc Pooled Asia Pac

3.25 %

Hdfc Trustee Company Ltd. A/C Hdfc Growth Opportunities Fund

2.26 %

Ntasain Discovery Master Fund

2.05 %

Life Insurance Corporation Of India

1.76 %

Promoters

Saldanha Family Trust

45.45 %

Blanche Elizabeth Saldanha

0.39 %

Glenn Mario Saldanha

0.35 %

Cherylann Maria Pinto

0.27 %

Robin Joseph Pinto

0.18 %

Others

Ashish Dhawan

1.81 %

Iepf

0.08 %

Increase Decrease No change

Company Profile Detailed

The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain].

Belongs to (32 Indices) view more

Investors (111)

credit.s...

tata.bal...

oppeheim...

Followers (37)

nitin2

keerthi

deepak